使用铟-111 博来霉素二乙烯三胺五乙酸（In-111 BLEDTA）进行的临床研究，它是博来霉素与双功能螯合剂的肿瘤成像偶联物。

Clinical studies with In-111 BLEDTA, a tumor-imaging conjugate of bleomycin with a bifunctional chelating agent.

作者信息

Goodwin D A, Meares C F, DeRiemer L H, Diamanti C I, Goode R L, Baumert J E, Sartoris D J, Lantieri R L, Fawcett H D

出版信息

J Nucl Med. 1981 Sep;22(9):787-92.

Abstract

Indium-111 BLEDTA, a bleomycin analog containing an EDTA group, was used for tumor imaging in 110 patients with cancer. Scans with In-111 BLEDTA agreed with biopsy results in 75 of 95 patients (79% accuracy). A positive scan was obtained in 71 of 88 patients with a positive biopsy (81% sensitivity). In 21 of 95 patients (22%), the scan revealed tumor sites that had not been detected. The main limitation of visualization was the size of the tumor (1.5--2.0 cm diameter was the smallest size seen). Background radioactivity in the liver, spleen, and bone marrow also made tumor detection in these areas more difficult. The cause of this background, and of false-positive uptake in sites of inflammation, is correlated with specific radiolabeling of polymorphonuclear leukocytes by In-111 BLEDTA. Means of eliminating this background are discussed.

摘要

铟-111 博来霉素乙二胺四乙酸（In-111 BLEDTA）是一种含有乙二胺四乙酸基团的博来霉素类似物，用于110例癌症患者的肿瘤成像。95例患者中，铟-111 BLEDTA扫描结果与活检结果相符的有75例（准确率79%）。88例活检呈阳性的患者中，71例扫描结果为阳性（灵敏度81%）。95例患者中有21例（22%）扫描显示出未被检测到的肿瘤部位。可视化的主要限制因素是肿瘤大小（直径1.5 - 2.0厘米是可见的最小尺寸）。肝脏、脾脏和骨髓中的背景放射性也使得在这些区域检测肿瘤更加困难。这种背景以及炎症部位假阳性摄取的原因与铟-111 BLEDTA对多形核白细胞的特异性放射性标记有关。文中讨论了消除这种背景的方法。